Insider Trades23 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Sell | TECX | Peter Mcnamara | Chief Scientific Officer | 344 | $24.86 | $615.1M | -17.53% | +126.62% | $8.6K | +0.00% | 10b5-1 | Stalk |
| Jun 20, 2026 | Sell | TECX | Alise Reicin | Chief Executive Officer | 924 | $30.34 | $615.1M | -17.53% | +126.62% | $28.0K | -0.30% | — | Stalk |
| May 4, 2026 | Sell | TECX | Marcella K. Ruddy | Chief Medical Officer | 1,065 | $30.00 | $615.1M | -17.53% | +126.62% | $31.9K | -1.55% | 10b5-1 | Stalk |
| Apr 1, 2026 | Sell | TECX | Marcella K. Ruddy | Chief Medical Officer | 1,000 | $31.05 | $615.1M | -17.53% | +126.62% | $31.1K | -1.43% | 10b5-1 | Stalk |
| Mar 6, 2026 | Sell | TECX | Peter Mcnamara | Chief Scientific Officer | 8,977 | $22.06 | $615.1M | -17.53% | +126.62% | $198.0K | -1.28% | 10b5-1 | Stalk |
| Mar 6, 2026 | Sell | TECX | Marcella K. Ruddy | Chief Medical Officer | 10,000 | $30.00 | $615.1M | -17.53% | +126.62% | $300.0K | -12.54% | 10b5-1 | Stalk |
| Mar 3, 2026 | Sell | TECX | Peter Mcnamara | Chief Scientific Officer | 3,299 | $23.53 | $615.1M | -17.53% | +126.62% | $77.6K | -2.74% | 10b5-1 | Stalk |
| Feb 11, 2026 | Buy | TECX | Alise Reicin | Chief Executive Officer | 2,500 | $21.10 | $615.1M | -17.53% | +126.62% | $52.8K | +1.06% | — | Stalk |
| Feb 11, 2026 | Buy | TECX | Alise Reicin | Chief Executive Officer | 2,500 | $21.10 | $615.1M | -17.53% | +126.62% | $52.8K | +2.01% | — | Stalk |
| Feb 10, 2026 | Buy | TECX | Marc Schwabish | Chief Business Officer | 4,500 | $2.38 | $615.1M | -17.53% | +126.62% | $10.7K | +4.36% | — | Stalk |
| Feb 10, 2026 | Buy | TECX | Daniel Lochner | Chief Financial Officer | 6,000 | $21.61 | $615.1M | -17.53% | +126.62% | $129.7K | +23.04% | — | Stalk |
| Feb 4, 2026 | Sell | TECX | Marc Schwabish | Chief Business Officer | 1,619 | $23.22 | $615.1M | -17.53% | +126.62% | $37.6K | -7.06% | — | Stalk |
| Feb 4, 2026 | Sell | TECX | Peter Mcnamara | Chief Scientific Officer | 1,748 | $23.22 | $615.1M | -17.53% | +126.62% | $40.6K | -4.28% | — | Stalk |
| Feb 4, 2026 | Sell | TECX | Marcella K. Ruddy | Chief Medical Officer | 2,064 | $23.22 | $615.1M | -17.53% | +126.62% | $47.9K | -3.73% | — | Stalk |
| Feb 4, 2026 | Sell | TECX | Daniel Lochner | Chief Financial Officer | 2,077 | $23.22 | $615.1M | -17.53% | +126.62% | $48.2K | -7.39% | — | Stalk |
| Feb 4, 2026 | Sell | TECX | Alise Reicin | Chief Executive Officer | 4,104 | $23.22 | $615.1M | -17.53% | +126.62% | $95.3K | -1.72% | — | Stalk |
| Dec 31, 2025 | Buy | TECX | Alise Reicin | Chief Executive Officer | 10,966 | $2.38 | $615.1M | -17.53% | +126.62% | $26.1K | +4.37% | — | Stalk |
| Dec 22, 2025 | Buy | TECX | Peter Mcnamara | Chief Scientific Officer | 7,000 | $2.98 | $615.1M | -17.53% | +126.62% | $20.9K | +11.88% | — | Stalk |
| Jun 20, 2025 | Sell | TECX | Alise Reicin | Chief Executive Officer | 859 | $19.81 | $615.1M | -17.53% | +126.62% | $17.0K | -0.40% | — | Stalk |
| Feb 5, 2025 | Buy | TECX | Daniel Lochner | Chief Financial Officer | 4,617 | $54.14 | $615.1M | -17.53% | +126.62% | $250.0K | — | — | Stalk |
| Jan 28, 2025 | Buy | TECX | Marc Schwabish | Chief Business Officer | 2,700 | $2.38 | $615.1M | -17.53% | +126.62% | $6.4K | +3.05% | — | Stalk |
| Dec 9, 2024 | Buy | TECX | Marc Schwabish | Chief Business Officer | 2,000 | $2.38 | $615.1M | -17.53% | +126.62% | $4.8K | +2.24% | — | Stalk |
| Dec 3, 2024 | Buy | TECX | Peter Mcnamara | Chief Scientific Officer | 3,500 | $2.38 | $615.1M | -17.53% | +126.62% | $8.3K | +7.75% | — | Stalk |